Pharma channel feed

This ex­trav­a­gant par­ty dur­ing #BIO18 fea­tured top­less dancers, and in­dus­try lead­ers are not pleased

7 years ago

UK bank launch­es £2.5B plan to fund in­no­va­tion, with a spe­cial place for its long-ail­ing biotech scene

7 years ago
Financing

Step­ping in­to the pric­ing de­bate, FDA chief Scott Got­tlieb pro­pos­es new re­im­burse­ment idea for an­tibi­otics

7 years ago

With a big as­sist from the FDA, Sage plots a swift march through PhI­II for oral de­pres­sion drug -- mar­ket cap swells $1B-plus

7 years ago

No­var­tis hands Re­genxbio $100M in fast cash for vec­tor tech

7 years ago

Gene edit­ing stocks get bush­whacked as new stud­ies high­light CRISPR/Cas9 can­cer risks

7 years ago

Alex­ion cau­tious­ly steps over to the C6 path­way with an ear­ly-stage de­vel­op­ment deal tied to buy­out op­tion

7 years ago

Sanofi builds on mR­NA al­liances with an $805M pact for Ron Re­naud’s Trans­late Bio

7 years ago
R&D

Ab­b­Vie, Roche post a big win with a block­buster FDA OK for Ven­clex­ta/Rit­ux­an com­bo for leukemia

7 years ago

Vi­su­al­ize: AS­CO 2018's win­ners and losers

8 years ago
R&D

Di­a­betes gi­ant No­vo said to con­sid­er up to 3,000 lay­offs as US pric­ing storms gath­er: re­port

8 years ago
R&D

Re­lo­cat­ing its US HQ to Boston, French phar­ma Ipsen to add 250 jobs

8 years ago
R&D

Gates Foun­da­tion sets up biotech-like in­sti­tute in hands-on ef­fort to spur drug de­vel­op­ment for ne­glect­ed dis­eases

8 years ago
R&D

That big Bio­gen deal you were wait­ing for? Keep wait­ing

8 years ago

Mega-block­buster? Pfiz­er lines up for a snap re­view of its PARP drug ta­la­zoparib — and a launch in­to a crowd­ed mar­ket

8 years ago

Genen­tech dives deep­er in­to the mi­cro­bio­me, ink­ing $534M deal with Mi­cro­bi­ot­i­ca to de­vel­op IBD meds

8 years ago

Pick­ing up the pieces left from an Alzheimer’s im­plo­sion, Ax­o­vant is start­ing over by div­ing in­to gene ther­a­py

8 years ago
R&D

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

8 years ago
R&D

With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

8 years ago
China

Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic can­cer drug suc­cess

8 years ago
R&D

FDA stalls yet an­oth­er Her­ceptin copy­cat, is­su­ing re­sponse let­ter to Am­gen/Al­ler­gan

8 years ago

FDA quash­es block­buster dreams at Eli Lil­ly and In­cyte, of­fer­ing a se­vere­ly lim­it­ed ap­proval for Olu­mi­ant

8 years ago

The FDA and the EMA go their sep­a­rate ways on DMD: CHMP slaps down Sarep­ta but of­fers ri­val PTC an ex­pand­ed mar­ket

8 years ago

Di­min­ish­ing the FDA’s pow­er was my in­tent: Right-to-try au­thor scolds Scott Got­tlieb as agency im­ple­ments new law

8 years ago
First page Previous page 299300301302303304305 Next page Last page
A service from the Financial Times